Aardvark Therapeutics暂停针对PWS的Ard-101三期HERO及OLE试验;最新指引预计2026年第二季度公布

美股速递
Mar 24

Aardvark Therapeutics公司宣布,已暂停其候选药物Ard-101用于治疗普瑞德-威利综合征(PWS)的三期HERO临床试验及开放标签扩展(OLE)研究。

公司表示,预计将在2026年第二季度提供关于该研发项目下一步计划的进一步指导。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10